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Abstract The synthesis of both enantiomers of a key intermediate in
the synthesis of halofuginone was accomplished by a Candida antarctica
lipase B (CAL-B)-catalyzed kinetic resolution of the corresponding race-
mate. When the resolution was carried out in the versatile solvent cy-
clopentyl methyl ether (CPME) using p-chlorophenylbutyrate (PCPB) as
the acylating reagent, the highest enantiomeric ratio (E) values were
measured, and highly enantioenriched (95% ee) compounds could be
obtained in a single iteration. As an example, one of the two enantio-
mers was used as a starting material to prepare (+)-halofuginone in a
three-step procedure.
Key words biocatalysis, lipase, kinetic resolution, halofuginone
Febrifugine (1, Figure 1) is a naturally occurring com-
pound first isolated from the leaves of the Asian medicinal
plant Dichroa febrifuga, traditionally used to reduce fever
from malaria infection.1 However, translation of febrifugine
into a medicine failed because of serious side effects such as
nausea, vomiting, and liver damage.2 For this reason ana-
logues were synthesized to improve the activity/toxicity
profile. Amongst these, halofuginone (2, Figure 1), in which
the metabolically vulnerable quinazoline protons in 1 were
replaced by chlorine and bromine atoms, besides demon-
strating effective antiprotozoal activity against several spe-
cies of Eimeria in poultry,3 proved, in its racemic form, to
possess a broad spectrum of pharmacological activities
such as antifibrosis,4 antitumor,5 and growth-promoting
functions.6 As reports on the biological activity of the iso-
lated enantiomers of 2 are rather limited,  in the recent de-
cades many efforts have been devoted to the enantioselec-
tive synthesis of halofuginone, and febrifugine as well, with
the N-protected 3-hydroxypiperidine derivatives 3 (Figure
1), possessing (2R,3S) absolute configuration, being the key
target intermediates.8–10
Figure 1  Structure of febrifugine (1), halofuginone (2), and 3-hydroxy-
piperidine derivatives 3
More recently, strategies explored for the enantioselec-
tive synthesis of 3a (R = Cbz) were based on the use of start-
ing materials from the chiral pool such as D-arabinose11 and
the installation of new stereocenters by organocatalysis.12,13
Despite the tremendous efficacy of enzymes in providing
enantiopure compounds, to our knowledge only Evans has
reported on the enantiodivergent asymmetric synthesis of
febrifugine, halofuginone, and their hemiketals based on ki-
netic resolution (KR) of a linear alcohol (4, Scheme 1, a) cat-
alyzed by Candida antarctica lipase B.14 However, this ap-
proach required two iterations to provide one of the enan-
tiomers (alcohol (+)-4) with high optical purity (98% ee)
but in low (27%) overall yield. Encouraged by our recent re-
sults in the lipase-catalyzed KR of 3-hydroxypiperidine de-
rivatives,15a the report by Yoshimura et al. on the efficient
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continuation of our studies on the enantioselective synthe-
sis of (poly)hydroxypiperidine alkaloids by enzyme15b,c and
transition-metal catalysis,15d–j we decided to establish a
practical synthetic protocol for the synthesis of both enan-
tiomers of 3a with high optical purity by lipase-catalyzed
KR of the corresponding racemate (Scheme 1, c). Moreover,
looking at a possible industrial application of our approach
to 3a, we decided to study this enzymatic process in both
green and nonconventional media, in particular focusing on
cyclopentyl methyl ether (CPME). This is a versatile solvent,
suitable for applications in biotechnology and biorefineries
due to its properties such as low peroxide formation rate,
stability under basic and acidic conditions, relatively high
boiling point, and low water solubility and water content.17
To the same end, for the synthesis of racemic 3a, we also
slightly modified the shortest known route from a commer-
cial achiral precursor in order to reduce the number of
chromatographic purifications. In this way we could estab-
lish an efficient protocol of possible industrial interest, use-
ful for rapid preparation of both enantiomers of halofugi-
none for comparative bioassays.
Scheme 1  Previous literature reports on EKR and the approach report-
ed herein
Thus, commercially available, N-Cbz-protected 1,2,3,4-
tetrahydropyridine 8 (Scheme 2) was treated with Oxone®
(2 equiv) in acetone/water and in the presence of K2CO3 (2
equiv) to obtain hemiaminal 9 (96% yield)18 that, as the
crude product, was subjected to Horner–Wadsworth–
Emmons (HWE) olefination by reaction with phosphonate
1019 to give alcohol 11 with E geometry.9 Treatment of
crude 11 with BF3·Et2O in anhydrous acetonitrile eventually
provided racemic 3a contaminated with furan derivative 12
(15% by 1H NMR analysis).20 The advantage of the HWE over
the Wittig olefination of the same compound20a is that only
one chromatography of crude 3a on silica gel is necessary to
separate this product from both 12 and residual unreacted
phosphonate 10.20b In this way, pure (±)-3a could be ob-
tained in 50% yield over the three steps and the synthesis
could be rapidly carried out, usually on a 4 mmol scale,
whenever 3a was needed.
Scheme 2  Synthesis or racemic key intermediate 3
With racemic 3a in hand, we studied its enzymatic ki-
netic resolution (EKR) via lipase-catalyzed esterification in
solvents with low water content, focusing on the use of the
commercially available immobilized enzyme, iCALB (Candi-
da antarctica lipase B immobilized on acrylic resin, Novo-
zym® 435).21 This choice stemmed from the fact that we
had successfully previously used iCALB for the kinetic reso-
lution of hydroxylated piperidine derivatives.15 This en-
zyme was used as provided by the supplier without any
treatment prior use but we measured its esterification ac-
tivity of 1-octanol in CPME using vinyl acetate as acylating
reagent at 30 °C.22 At a substrate/enzyme ratio of 1:10 (0.19
mmol of substrate (S) and 1.9 mg of immobilized enzyme
(Enz)), substrate concentration 0.75 M, and 3.5 equiv of
vinyl acetate, the conversion into product after 5 min was
49%, corresponding to an activity value of 9.8 × 10-6
mmol(S)/[min × mg(Enz)]. The results of this study are re-
ported in Tables 1 and 2.
Starting with vinyl butyrate as the acylating agent we
then screened different solvents (Table 1), such as THF (logP
0.46), to compare with the standard solvents we had used
in our previous studies,15a–c 2-MeTHF (logP 1.36), and CPME
(logP 1.59).23 On the basis of very recent literature on the
use of Deep Eutectic Solvents (DES) as media for biocata-
lyzed transformations, we also employed two DES24 ob-
tained by mixing choline chloride with urea and glycerol,
respectively.25 The reactions were monitored by GLC and
stopped when the conversion was in the 40–50% range. The
first experiments (Table 1, entries 1–3) were carried out
with solvents dried by distillation over Na/benzophenone.
In all cases, the iCALB lipase preferentially catalyzed esteri-


















(a) Evans et al. Tetrahedron, 2017, 73, 5493
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with comparable E (enantiomeric ratio) values;26 although
in CPME (and to a lesser extent in 2-MeTHF) the reaction
was much faster (7 h). As interfacial activation is not known
for this lipase,27 the higher activity in the more lipophilic
CPME could be related to the increased hydrophobicity of
the hydration layer, which facilitates the access of the sub-
strate to the enzyme surface,28 and is in line with the in-
creased activity (and selectivity) observed in this solvent in
other CALB-catalyzed resolution processes.17 As the reac-
tion was faster in CPME with a high E value, we continued
our study with this solvent because of its specific proper-
ties as mentioned earlier.17
Table 1  iCALB-Catalyzed Kinetic Resolution of (±)-3a in Different Sol-
ventsa
Disappointing results were obtained in the two DES we
investigated (entries 6–8), in which reaction rates were un-
acceptably low despite several attempts at changing con-
centration, stirring rate, temperature, quantity of acylating
agent, using crushed lipase or adding a co-solvent (data not
shown). On the other hand, successful iCALB-catalyzed
transesterification was observed in the two DES we investi-
gated using a large excess of alcohol to convert vinyl laura-
te.25
These negative results are consistent with those ob-
tained by Petrenz et al. who attempted a lipase-catalyzed
KR of benzoin in DES with vinyl butyrate and found a much
lower activity (10% conversion after 48 h) than in CPME and
2-MeTHF, most likely due to mass-transfer limitations as a
result of high DES viscosity.29
We evaluated CPME as provided by the supplier, too (en-
try 4), observing just a slight decrease of the E value (68)
but not of the reaction rate. We measured the content of
water in CPME before (1330 ppm) and after distillation (255
ppm) over Na/benzophenone by Karl Fischer titration. Our
results show that the water content in commercial CPME is
not sufficiently high to affect the reaction rate, for example,
by competing with the substrate, at least under our condi-
tions, but has instead a small influence on the enantioselec-
tivity.30 The reaction rate was instead slight lower when
carried out in the presence of 4 Å molecular sieves (MS) and
in CPME dried over 4 Å MS for two days (entry 5).
The next experiments were carried out in CPME dis-
tilled over Na/benzophenone, changing the acylating agent,
in the attempt to further improve the E value (Table 2, en-
tries 1–7). In all cases, the reaction was slower than with vi-
nyl butyrate (Table 2, entry 1) but we were very satisfied to
observe that, with PCPB as the acylating agent, the E value
was very high (290) and the reaction was still reasonably
fast (24 h to reach 46% conversion). In general, the reaction
was much faster when carried out with vinyl esters (Table
2, entries 1, 6, 7) than with esters such as TFEB and TCEA
(Table 2, entries 2 and 5). Reducing the amount of enzyme
to a quarter (25 mg per mmol of substrate) the reaction rate
was, as expected, much lower (Table 2, entries 8 and 9),
without any significant effect on the enantiomeric ratio E.
When reducing the amount of acylating agent, while we did
not observe any variation in the reaction rate with vinyl bu-
tyrate (cf. Table 2, entries 9 and 11), the reaction did slow
down significantly when we used PCPB (cf. Table 2, entries
3 and 10). Despite this, we opted for the latter conditions
for a larger scale KR of (±)-3a (and the subsequent synthesis
of enantiopure halofuginone) to avoid using a relatively
large excess of the acylating agent, the residual amounts of
which can nevertheless be separated by chromatography
and recycled.
For the synthesis of (+)-halofuginone (Scheme 3) we
first resolved 2 mmol of (±)-3a using iCALB under the con-
ditions of Table 2, entry 10. Given the high enantioselectivi-
ty of the enzyme, only one iteration was necessary to ob-
tain in good yield highly enantioenriched compounds (–)-
3a (45%, 95% ee) and (+)-13a (44%). Hydrolysis of (+)-13a,
carried out in the presence of MeONa in anhydrous metha-
nol, then furnished alcohol (+)-3a (95% ee) in 89% yield. The
next steps of the synthesis were carried out as reported,14
by -bromination of (–)-3a with N-bromosuccinimide





1 THFe 25 45 94 88 94
2 2-MeTHFe 7.5 39 97 64 127
3 CPMEe,f 7 46 94 84 86
4 CPMEg 8 48 92 87 68
5 CPMEh 8.5 37 95 68 80
6 ChCl/ureai (1:2) 118 16 93 24 35
7 ChCl/urea (1:2) + 
CPME (10%)i,j
120 21 – – –
8 ChCl/glycerol 
(1:2)j
22 2 – – –
a Reaction carried out on 0.2 mmol of substrate at 30 °C; substrate concen-
tration: 0.76 M; enzyme (mg)/substrate (mmol) ratio: 100 mg mmol–1; 3.5 
equiv of acylating agent.
b Reaction monitored by GLC; conversion determined by 1H NMR spectros-
copy.
c Determined by HPLC analysis on a HPLC Lux® 5 m Amylose-1 (250 × 4.6 
mm) column; for (+)-13a after hydrolysis to alcohol (+)-3a.
d E was calculated by using the formula E = ln[(1 – eeS)/(1 + eeS/eeP)]/ln [(1 + 
eeS)/(1 + eeS/eeP)] as reported in ref. 26.
e Distilled over Na/benzophenone.
f Water content: 255 ppm.
g Commercial material; water content: 1330 ppm.
h Dried over 4 Å MS and reaction was carried out in the presence of 4 Å MS 
(130 mg mmol–1).
i Carried out at 50 °C.
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followed by the reaction of 14 (as crude product) with com-
mercially available cebrazolone (7-bromo-6-chloro-4(1H)-
quinazolinone) to give N-CBz-protected halofuginone (–)-
15 in 62% yield after chromatography. Finally, treatment
with HBr in acetic acid provided (+)-halofuginone hydro-
bromide 2 in 57% yield. Of course, by the same approach,
(–)-halofuginone with the same optical purity (95% ee)
could be obtained from (+)-3a.
In conclusion, we have demonstrated that the enantio-
divergent synthesis of a key intermediate in the preparation
of halofuginone can be accomplished by its enzymatic ki-
netic resolution using immobilized Candida antarctica li-
pase B. When the resolution was carried out in the CPME
solvent, using p-chlorophenylbutyrate (PCPB) as the acylat-
ing reagent, the highest enantiomeric ratio (E) values were
measured, providing almost enantiopure (95% ee) com-
pounds in a single iteration of the kinetic resolution. Since
the racemic material can be quickly obtained in three steps
from a commercially available piperidine derivative, with
only one chromatographic purification needed, our ap-
proach is an efficient and sustainable synthesis of halofugi-
none for further investigating the biological properties of
both enantiomers of this biologically active compound. As
an illustration, one of the two enantiomers was converted
into enantiopure (+)-halofuginone according to a literature
procedure.
Anhydrous solvents were prepared according to the standard tech-
niques. Commercially available reagents were used without further
purification. Chromatographic separations were performed under
pressure on silica gel 60 (Merck, 70–230 mesh) by using flash column
techniques; Rf values refer to TLC carried out on 0.25 mm silica gel
plates (F254) with the same eluent indicated for column chromatogra-
phy. 1H NMR (400 and 200 MHz) and 13C NMR (100.4 MHz) spectra
were recorded on Varian Inova (400 MHz) and Mercury (400 and 200
MHz) spectrometers in the specified deuterated solvent at 25 °C. 1H
NMR (600 MHz) and 13C NMR (150 MHz) spectra were recorded on a
Jeol ECZR600 spectrometer. Solvent references were set at  = 7.26
and 77.0 ppm (CDCl3), 2.50 and 39.5 ppm (DMSO-d6) in the 
1H NMR
and 13C NMR spectra, respectively. Mass spectrometric analyses were
carried out by direct inlet of a 10 ppm solution in MeOH into an LCQ
Fleet Ion Trap LC–MS system (Thermo Fisher Scientific) with an elec-
trospray ionization (ESI) interface in the positive ion mode. HPLC
analyses were carried out with a Dionex Ultimate 3000 instrument,
using a Lux 5 m Amylose-1 column (250 × 4.6 mm) and eluting at 0.5
mL min–1 flow rate in isocratic 30% IPA, 70% hexane. Signals were
monitored at  = 223 nm with a UV detector. Compound 8 is commer-
cially available or can be prepared as reported.18 Compounds (+)-
2·2HBr,14 (±)-3a,20 (–)-3a,9 (+)-3a,9 9,18 10,19 11,20 14,14 and (–)-1514
are known. Candida antarctica lipase B immobilized on acrylic resin
(Novozym® 435) was purchased from Strem Chemicals, Inc.









1 VB 7 46 94 84 86
2 TFEB 96 39 98 66 197
3 PCPB 24 46 98 88 290
4e PCPB 28 43 97 75 149
5 TCEA 49 42 95 74 85
6 VA 18 44 91 81 53
7 IPA 25 42 95 78 93
8f PCPB 144 (6 days) 44 98 79 240
9f VB 76 47 93 88 80
10g PCPB 62 50 95 95 146
11f,g VB 76 49 94 90 100
a Reaction carried out on 0.2 mmol of substrate at 30 °C; substrate concen-
tration: 0.76 M; enzyme (mg)/substrate (mmol) ratio: 100 mg mmol–1; 
CPME distilled over Na/benzophenone; 3.5 equiv of acylating agent (VB = 
vinyl butyrate; VA = vinyl acetate; TFEB = trifluoroethyl butyrate; PCPB = p-
chlorophenyl butyrate; TCEA = trichloroethyl acetate; IPA = isopropenyl ac-
etate).
b Reaction monitored by GLC; conversion and determined by 1H NMR spec-
troscopy.
c Determined by HPLC analysis on a HPLC Lux® 5 m Amylose-1 (250 × 4.6 
mm) column; for (+)-13a/13a′ after hydrolysis to alcohol (+)-3a.
d E was calculated by using the formula E = ln[(1 – eeS)/(1 + eeS/eeP)]/ln [(1 + 
eeS)/(1 + eeS/eeP)] as reported in ref. 26.
e CPME dried over 4 Å MS.
f Enzyme (mg)/substrate (mmol) ratio: 25 mg mmol–1.















(+)-13a R = n-Pr
(+)-13a' R = Me
O
RO
Scheme 3  Synthesis of (+)-halofuginone hydrobromide
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Chloroacetone (2 mL, 25 mmol) was added to a suspension of KI
(4.6 g, 27.5 mmol) in anhydrous MeCN (10 mL) and anhydrous acetone
(10 mL), and the reaction was stirred at room temperature for 1 h.
Then triethylphosphite (4.34 mL, 25 mmol) was added dropwise over
10 min. After 16 h, the reaction mixture was quenched with water
(20 mL) and extracted with EtOAc (3 × 40 mL). The combined organic
layers were washed with water (2 × 60 mL), brine (60 mL), dried over
Na2SO4, filtered, and concentrated in vacuo. The yield of product 10
(80%) was calculated by 1H NMR analysis, using MeNO2 as internal
standard. Crude 10 was then used without further purification.
1H NMR (200 MHz, CDCl3):  = 4.22–4.07 (m, 4 H), 3.08 (d, J = 22.8 Hz,
2 H), 2.32 (s, 3 H), 1.34 (t, J = 7.0 Hz, 6 H) ppm.
3-Hydroxy-2-(2-oxopropyl)piperidine-1-carboxylic Acid Benzyl 
Ester ((±)-3a)
To a solution of 8 (696 L, 3.6 mmol) and K2CO3 (1 g, 7.2 mmol) in
acetone (12 mL) and water (12 mL) at 0 °C was added dropwise a solu-
tion of Oxone® (4.42 g, 7.2 mmol) in water (30 mL) over 5 min, and
the reaction mixture was stirred at room temperature for 2 h. Then
the mixture was poured into ice and water (40 mL) and, after separa-
tion of the layers, the aqueous one was extracted with EtOAc (3 × 40
mL). The combined organic layers were washed with brine (40 mL),
dried over Na2SO4, filtered, and concentrated under reduced pressure
to afford the crude intermediate 9 in 96% yield as a colorless oil, which
was used in the next step without further purification.18
1H NMR (200 MHz, CDCl3):  (mixture of rotamers) = 7.39–7.30 (m, 5
H), 5.77–5.70 (m, 1 H, major), 5.60–5.54 (m, 1 H, minor), 5.14 (s, 2 H),
3.96–3.77 (m, 1 H, major), 3.68–3.51 (m, 1 H, minor), 3.19 (td, J = 12.4,
3.6 Hz, 1 H, minor), 3.04 (td, J = 12.8, 3.2 Hz, 1 H, major), 2.34–2.21
(m, 1 H, major), 2.08–1.98 (m, 1 H, minor), 1.97–1.42 (m, 4 H) ppm.
Crude 10 (1.67 g, 8.6 mmol) was dissolved in anhydrous THF (38 mL)
and treated with NaH 60% (w/w) in mineral oil (344 mg, 8.6 mmol)
for 30 min at 0 °C. A solution of crude hemiaminal 9 (867 mg, 3.45
mmol) in anhydrous THF (17 mL) was then added and the mixture al-
lowed to warm to room temperature and stirred overnight. Then Et2O
(40 mL) was added, and the organic layer was washed with a saturat-
ed aqueous solution of NH4Cl (2 × 40 mL), brine (40 mL), and dried
over Na2SO4. After filtration and evaporation of the solvent, the oily
residue containing olefin 11 was used as such in the next step.20
1H NMR (200 MHz, CDCl3):  = 7.37–7.32 (m, 5 H), 6.74 (dd, J = 16.0,
5.0 Hz, 1 H), 6.27 (dd, J = 16.0, 1.4 Hz, 1 H), 5.09 (s, 2 H), 4.94–4.85 (m,
1 H), 4.29–4.23 (m, 1 H), 3.32–3.17 (m, 2 H), 2.48–2.38 (m, 1 H), 2.26
(s, 3 H), 1.74–1.57 (m, 4 H) ppm.
Crude olefin 11 (3.45 mmol) in acetonitrile (34.5 mL) was treated
with BF3·Et2O (213 L, 1.73 mmol) at 0 °C. After 25 min a saturated
aqueous solution of NaHCO3 (55 mL) was added and the product ex-
tracted with EtOAc (2 × 55 mL). The combined organic extracts were
washed with brine (30 mL), dried over Na2SO4, filtered, and concen-
trated under reduced pressure. The crude product was purified by
flash chromatography (n-hexane/EtOAc, 1:2, Rf = 0.29) to afford pure
(±)-3a (582 mg, 2 mmol) in 50% yield as a yellow oil. Spectroscopic
and analytical data are identical to those reported in the literature.20
1H NMR (400 MHz, CDCl3):  = 7.34–7.27 (m, 5 H), 5.11 (s, 2 H), 4.73
(m, 1 H), 4.13–4.00 (m, 1 H), 3.84–3.75 (m, 1 H), 2.86 (t, J = 12.0 Hz, 1
H), 2.63 (d, J = 7.6 Hz, 2 H) 2.14 (br s, 3 H), 1.89 (qt, J = 13.2, 4.8 Hz, 1
H), 1.79–1.71 (m, 1 H), 1.70–1.60 (m, 1 H), 1.45–1.36 (m, 1 H) ppm.
Lipase-Catalyzed Kinetic Resolution of (±)-3a
iCAL-B (200 mg) was added to a solution of (±)-3a (582 mg, 2 mmol)
in anhydrous CPME (2.6 mL) at 30 °C and, after 10 min, p-chlorophe-
nyl butyrate (795 mg, 4 mmol) was added. The reaction mixture was
stirred, and the progress of EKR process was monitored by GLC. After
72 h, the conversion reached 50%, and the reaction was stopped by
filtration through a thin layer of Celite® and the filter cake was
washed with EtOAc (3 × 5 mL). After evaporation of the solvent, the
crude product was purified by flash chromatography (n-hexane/EtOAc,
1:1) to give (+)-13a (318 mg, 44%; Rf = 0.40) as a colorless oil (95% ee),
and (–)-3a (262 mg, 45%; Rf = 0.18) as a clear yellow oil.
3-Hydroxy-2-(2-oxopropyl)piperidine-1-carboxylic Acid Benzyl 
Ester ((–)-3a)9
[]D
20 –19.9 (c 0.68, CHCl3). Spectroscopic data are identical to those
reported for (±)-3a.
3-Butyryloxy-2-(2-oxopropyl)piperidine-1-carboxylic Acid Benzyl 
Ester ((+)-13a)
[]D
20 + 50.8 (c 0.7, CHCl3).
1H NMR (400 MHz, CDCl3):  = 7.34–7.29 (m, 5 H), 5.13 (br s, 2 H),
4.83 (br d, J = 38.6 Hz, 2 H), 4.24–3.99 (br m, 1 H), 2.99–2.81 (m, 1 H),
2.72–2.60 (m, 2 H), 2.28–2.06 (br m, 5 H), 1.84–1.73 (br m, 3 H), 1.60–
1.44 (br m, 3 H), 0.90 (t, J = 7.2 Hz, 3 H) ppm.
13C NMR (100.4 MHz, CDCl3):  (mixture of rotamers) = 205.9 and
205.0, 172.8, 155.7, 136.6, 128.4 (2 C), 127.9, 127.8 (2 C), 68.9, 67.2,
51.1, 43.4, 38.9, 36.2, 29.7, 23.7, 19.6, 18.3, 13.6 ppm.
MS (ESI): m/z (%) = 745 [2M + Na]+ (100), 384 [M + Na]+ (55).
Anal. Calcd for C20H27NO5: C, 66.46; H, 7.53; N, 3.88. Found: C, 66.27;
H, 7.31; N, 3.76.
3-Hydroxy-2-(2-oxopropyl)piperidine-1-carboxylic Acid Benzyl 
Ester ((+)-3a)9
To a solution of (+)-13a (318 mg, 0.88 mmol) in anhydrous MeOH (6
mL) cooled to 0 °C was added MeONa (95 mg, 1.76 mmol), and the
reaction was stirred at room temperature overnight. A saturated
aqueous solution of NH4Cl (880 L) was then added and the reaction
mixture concentrated under reduced pressure. Water (88 mL) and
EtOAc (88 mL) were added to the residue, and, after separation of the
phases, the aqueous phase was further extracted with EtOAc (3 × 50
mL) and the combined organic extracts were dried over Na2SO4. After
filtration and evaporation of the solvent, crude (+)-3a was purified by
flash chromatography (n-hexane/EtOAc, 1:1; Rf = 0.18), affording pure
(+)-3a (227 mg, 89%) as a clear yellow oil (95% ee). []D
20 +23.2 (c 0.7,
CHCl3). Spectroscopic data are identical to those reported for (±)-3a.
2-[3-(7-Bromo-6-chloro-4-oxo-4H-quinazolin-3-yl)-2-oxopropyl]-
3-hydroxypiperidine-1-carboxylic Acid Benzyl Ester [(–)-N-Cbz-
Protected Halofuginone, (–)-15]14
DIPEA (502 L, 2.88 mmol ) and TMSOTf (521 L, 2.88 mmol) were
added to a solution of (–)-3a (262 mg, 0.90 mmol) in anhydrous DCM
(16 mL), cooled to 0 °C (ice bath). After 20 min, NBS (224 mg, 1.26
mmol) was added, the ice bath removed and, after 20 min, the reac-
tion was stopped by dilution with DCM (16 mL). The organic solvent
was washed with water (2 × 16 mL), brine (16 mL), and dried over
Na2SO4. After filtration and evaporation of the solvent, crude -bro-
minated intermediate 14 was obtained and used as such in the next
step.SynOpen 2021, 5, 145–151
150
E. De Marchi et al. PaperSynOpen1H NMR (400 MHz, CDCl3):  (mixture of rotamers) = 7.38–7.28 (m, 5
H), 5.11 (s, 2 H), 4.72 (t, J = 6.8 Hz, 1 H), 4.05 (br s, 1 H), 3.83 (br s, 2 H),
3.01–2.87 (m, 2 H), 2.84 (d, J = 8.0 Hz, 2 H, major), 2.80 (d, J = 8.0 Hz, 2
H, minor), 2.85–2.79 (m, 1 H), 1.89 (qt, J = 12.8, 4.4 Hz, 1 H), 1.82–1.73
(m, 1 H), 1.72–1.63 (m, 1 H), 1.48–1.39 (m, 1 H) ppm.
Crude 14 was dissolved in anhydrous DMF (10 mL) and reacted with
7-bromo-6-chloro-4(1H)-quinazolinone (cebrazolone, 234 mg, 0.90
mmol) in the presence of K2CO3 (124 mg, 0.90 mmol) at room tem-
perature. After 18 h, the reaction mixture was diluted with EtOAc (20
mL), washed with water (2 × 20 mL), and, after separation of the
phases, the aqueous phase was further extracted with EtOAc (3 × 20
mL). The combined organic extracts were washed with brine (40 mL)
and dried over Na2SO4. After filtration and evaporation of the solvent,
the crude product was purified by flash chromatography (EtOAc; Rf =
0.17) to afford (–)-N-Cbz-protected halofuginone (–)-15 (307 mg,
62%) as a white solid. Spectroscopic and analytical data are in accor-
dance with those reported.14
[]D
21 – 21.4 (c 0.59, CHCl3).
1H NMR (400 MHz, CDCl3):  = 8.28 (s, 1 H), 8.00 (s, 1 H), 7.95 (br s, 1
H), 7.35–7.28 (m, 5 H), 5.11 (s, 2 H), 5.01–4.78 (m, 1 H), 4.71 (t, J = 6.4
Hz, 1 H), 4.07–3.95 (m, 1 H), 3.88 (s, 1 H), 3.08–2.96 (m, 1 H), 2.85–
2.77 (m, 2 H), 2.60 (br s, 1 H), 1.90 (qt, J = 12.8, 4.4 Hz, 1 H), 1.83–1.72
(m, 2 H), 1.51–1.43 (m, 1 H), 0.90–0.80 (m, 1 H) ppm.
2-[3-(7-Bromo-6-chloro-4-oxo-4H-quinazolin-3-yl)-2-oxopropyl]-
3-hydroxypiperidinium Bromide ((+)-2·2HBr)14
(–)-N-Cbz-protected halofuginone (–)-15 (307 mg, 0.56 mmol) in 33%
HBr in AcOH (8.4 mL) was stirred at room temperature for 3 h. Then
the reaction mixture was diluted with MeOH (8.4 mL), triturated with
Et2O (3 × 8.4 mL) and dried under reduced pressure to afford (+)-
2·2HBr (184 mg, 57%) as a white solid with analytical and spectro-
scopic data in accordance with those reported in the literature.14
1H NMR (600 MHz, DMSO-d6):  = 8.79–8.67 (m, 2 H), 8.30 (s, 1 H),
8.22 (s, 1 H), 8.17 (s, 1 H), 5.14–5.08 (m, 2 H), 3.53 (td, J = 9.6, 4.2 Hz, 1
H), 3.35–3.29 (m, 1 H), 3.23 (dd, J = 17.4, 5.4 Hz, 1 H), 3.18–3.13 (m, 1
H), 2.93 (dd, J = 17.4, 6.0 Hz, 1 H), 2.92–2.85 (m, 1 H), 1.94–1.89 (m, 1
H), 1.83–1.77 (m, 1 H), 1.68–1.59 (m, 1 H), 1.48–1.42 (m, 1 H) ppm.
13C NMR (150 MHz, DMSO-d6):  = 200.7, 158.7, 149.6, 147.3, 132.5,
131.9, 128.5, 126.9, 121.8, 66.8, 56.2, 54.5, 43.0, 30.6, 20.2 ppm.
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